NCT07561541

Brief Summary

The goal of this clinical trial is to learn if taking an antibiotic pill for 7 days after surgery reduces the risk of wound infection in adults with poorly controlled diabetes who have surgery to fix a broken bone in the leg, ankle, or foot. It will also learn about the safety of the extended antibiotic course. The main questions it aims to answer are: Does a 7-day antibiotic course after surgery lower the rate of wound infection within 90 days? What medical problems do participants have when taking the extended antibiotic course? Researchers will compare a 7-day course of an oral antibiotic (cefadroxil) to standard care (no additional antibiotics after surgery) to see if the extended course reduces infections. Participants will: Take an antibiotic pill or receive standard care for 7 days after surgery Receive a phone call from the study team about 1 week after surgery Visit the clinic at 3 weeks, 6 weeks, and 3 months after surgery for checkups

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
20mo left

Started Apr 2026

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress6%
Apr 2026Dec 2027

Study Start

First participant enrolled

April 1, 2026

Completed
23 days until next milestone

First Submitted

Initial submission to the registry

April 24, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 1, 2026

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

May 1, 2026

Status Verified

April 1, 2026

Enrollment Period

1.8 years

First QC Date

April 24, 2026

Last Update Submit

April 24, 2026

Conditions

Keywords

DiabetesLower extremity fractureExtended oral antibiotic prophylaxis

Outcome Measures

Primary Outcomes (1)

  • Surgical site infection

    Superficial infection (a wound with erythema, warmth, or drainage that is treated with oral antibiotics or wound care) and deep infection (per fracture-related infection definition).

    90 days

Secondary Outcomes (2)

  • Antibiotic-related adverse effects

    90 days

  • Compliance with antibiotic regimen

    1 week

Study Arms (2)

Control

NO INTERVENTION

Standard of care (no extended oral antibiotic prophylaxis)

Intervention

EXPERIMENTAL

Extended oral antibiotic therapy

Drug: Cefadroxil 500 mg CapsulesDrug: ClindamycinDrug: Bactrim DS

Interventions

Cefadroxil 500 mg, twice a day for 7 days

Also known as: Duricef
Intervention

Clindamycin 300 mg, three times a day for 7 days

Intervention

Bactrim DS, twice a day for 7 days

Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Low extremity fracture requiring surgical treatment
  • Uncontrolled diabetes (HbA1c \> 7.0 or random glucose \> 200 mg/dL)
  • Age 18 years or older
  • Able to provide informed consent
  • English or Spanish speaker

You may not qualify if:

  • Known allergy to prescribed antibiotic and pre-determined alternatives
  • Open fractures
  • Current infection requiring antibiotic treatment
  • Immunocompromised status (chemotherapy, immunosuppressant medications)
  • End-stage renal disease that medication dosing cannot be adjusted for
  • Pregnant or breast-feeding
  • Unable to comply with follow-up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

USC

Los Angeles, California, 90033, United States

RECRUITING

University Medical Center of El Paso

El Paso, Texas, 79905, United States

RECRUITING

Texas Tech Health El Paso

El Paso, Texas, 79912, United States

RECRUITING

Related Publications (4)

  • Lipson S, Pagani NR, Moverman MA, Puzzitiello RN, Menendez ME, Smith EL. The Cost-Effectiveness of Extended Oral Antibiotic Prophylaxis for Infection Prevention After Total Joint Arthroplasty in High-Risk Patients. J Arthroplasty. 2022 Oct;37(10):1961-1966. doi: 10.1016/j.arth.2022.04.025. Epub 2022 Apr 25.

    PMID: 35472436BACKGROUND
  • Dasari SP, Kanumuri SD, Yang J, Manner PA, Fernando ND, Hernandez NM. Extended Prophylactic Antibiotics for Primary and Aseptic Revision Total Joint Arthroplasty: A Meta-Analysis. J Arthroplasty. 2024 Sep;39(9S2):S476-S487. doi: 10.1016/j.arth.2024.01.014. Epub 2024 Jan 17.

    PMID: 38237874BACKGROUND
  • Inabathula A, Dilley JE, Ziemba-Davis M, Warth LC, Azzam KA, Ireland PH, Meneghini RM. Extended Oral Antibiotic Prophylaxis in High-Risk Patients Substantially Reduces Primary Total Hip and Knee Arthroplasty 90-Day Infection Rate. J Bone Joint Surg Am. 2018 Dec 19;100(24):2103-2109. doi: 10.2106/JBJS.17.01485.

    PMID: 30562290BACKGROUND
  • Kheir MM, Dilley JE, Ziemba-Davis M, Meneghini RM. The AAHKS Clinical Research Award: Extended Oral Antibiotics Prevent Periprosthetic Joint Infection in High-Risk Cases: 3855 Patients With 1-Year Follow-Up. J Arthroplasty. 2021 Jul;36(7S):S18-S25. doi: 10.1016/j.arth.2021.01.051. Epub 2021 Jan 23.

    PMID: 33589279BACKGROUND

MeSH Terms

Conditions

Diabetes Mellitus

Interventions

CefadroxilClindamycinTrimethoprim, Sulfamethoxazole Drug Combination

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

CephalexinCephalosporinsbeta-LactamsLactamsAmidesOrganic ChemicalsThiazinesSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsLincomycinLincosamidesPyrrolidinesHeterocyclic Compounds, 1-RingGlycosidesCarbohydratesSulfamethoxazoleBenzenesulfonamidesSulfonamidesSulfanilamidesAniline CompoundsAminesBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsSulfonesTrimethoprimPyrimidinesDrug CombinationsPharmaceutical Preparations

Central Study Contacts

Taylor M Yong, MD, MS

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

April 24, 2026

First Posted

May 1, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

May 1, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations